Advancements in Cystic Fibrosis Treatment

Increased Life Expectancy

Since the identification of cystic fibrosis (CF) in 1938, life expectancy for individuals with CF has significantly improved. Key treatments, including antibiotics and physical therapy, have contributed to extending life expectancy into a person’s 30s. However, these therapies have limitations as they do not address the underlying cause of CF, which is a genetic mutation. Recent studies indicate that gene therapy may offer a way to alleviate symptoms and enhance the quality of life for those affected by this condition.

Understanding Cystic Fibrosis

Cystic fibrosis is primarily associated with a genetic mutation affecting the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This mutation often results from faulty genetic instructions, leading to either insufficient production or a complete absence of the CFTR protein. This protein is crucial for regulating water movement in tissues and for the production of mucus, sweat, saliva, tears, and digestive enzymes. Low CFTR levels disrupt the normal function of the lungs, pancreas, liver, intestines, and reproductive organs. Patients with CF typically produce excessive mucus, which impairs water balance in tissues, trapping bacteria and resulting in infections and inflammation in the airways.

Promising Gene Therapy Findings

A recent clinical trial demonstrated the potential of antisense oligonucleotides (ASO) in gene therapy for cystic fibrosis. ASOs are molecules that can regulate protein levels within cells, and the study aimed to create functional versions of CFTR. By utilizing ASOs, researchers were able to instruct cells to produce imperfect versions of CFTR, which improved the function of lung cells. These findings are encouraging for the future of CF treatments, as they suggest the possibility of developing tailored therapies customized for individual patients, leading towards more personalized medicine.

References

1. Naehrig, S., Chao, C.-M., & Naehrlich, L. (2017). Cystic fibrosis. Deutsches Ärzteblatt International. https://doi.org/10.3238/arztebl.2017.0564
2. Liou, T. G. (2019). The clinical biology of cystic fibrosis transmembrane regulator protein. Chest, 155(3), 605–616. https://doi.org/10.1016/j.chest.2018.10.006
3. Bell, S. C., Mall, M. A., Gutierrez, H., Macek, M., Madge, S., Davies, J. C., Burgel, P.-R., Tullis, E., Castaños, C., Castellani, C., Byrnes, C. A., Cathcart, F., Chotirmall, S. H., Cosgriff, R., Eichler, I., Fajac, I., Goss, C. H., Drevinek, P., Farrell, P. M., … Ratjen, F. (2020). The future of cystic fibrosis care: A global perspective. The Lancet Respiratory Medicine, 8(1), 65–124. https://doi.org/10.1016/s2213-2600(19)30337-6
4. Shteinberg, M., Haq, I. J., Polineni, D., & Davies, J. C. (2021). Cystic fibrosis. The Lancet, 397(10290), 2195–2211. https://doi.org/10.1016/s0140-6736(20)32542-3
5. Kim, Y.J., Nomakuchi, T., Papaleonidopoulou, F. et al. Gene-specific nonsense-mediated mRNA decay targeting for cystic fibrosis therapy. Nat Commun 13, 2978 (2022). https://doi.org/10.1038/s41467-022-30668-y